Last update 17 May 2024

Pralatrexate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(2S)-2-((4-((1RS)-1-((2,4-Diaminopteridin-6-yl)methyl)but-3-ynyl)benzoyl)amino)pentanedioic acid, (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid, 10-Propargyl-10-deazaaminopterin
+ [7]
Target
Mechanism
DHFR inhibitors(Dihydrofolate reductase inhibitors)
Drug Highest PhaseApproved
First Approval Date
US (24 Sep 2009),
RegulationAccelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (JP)
Login to view First Approval Timeline

Structure

Molecular FormulaC23H23N7O5
InChIKeyOGSBUKJUDHAQEA-WMCAAGNKSA-N
CAS Registry146464-95-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Peripheral T-Cell Lymphoma
US
24 Sep 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
T-Cell LymphomaNDA/BLA
EU
-
Peripheral T-cell lymphoma unspecified recurrentPhase 3
CN
10 Sep 2015
Peripheral T-cell lymphoma unspecified recurrentPhase 3
CN
10 Sep 2015
Peripheral T-cell lymphoma unspecified recurrentPhase 3
CN
10 Sep 2015
Peripheral T-cell lymphoma unspecified refractoryPhase 3
CN
10 Sep 2015
Peripheral T-cell lymphoma unspecified refractoryPhase 3
CN
10 Sep 2015
Peripheral T-cell lymphoma unspecified refractoryPhase 3
CN
10 Sep 2015
Multiple MyelomaPhase 2
US
09 Sep 2013
B-Cell LymphomaPhase 2
US
01 Sep 2009
Non-small cell lung cancer stage IIIBPhase 2
US
01 Jan 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
14
ydmdyykzdu(saeoctlzuc) = lqifsvtlru ervmgwnewl (isfzjlqxri )
-
22 Mar 2024
Phase 1
33
CHOP + Folotyn 30 mg/m2 (Fol-CHOP)
tmwjgjlxhy(vevfuqdgmm) = 21.2% diplxfjfwz (yohzkuvwxh )
Positive
23 Jan 2024
Phase 3
21
(Pralatrexate Arm)
jwqfnhxjtc(jyyltumigc) = wgvrpykxfz renjiarntp (pdaoqgczku, doefijlgih - cnomcrkxsl)
-
19 Nov 2021
vitamin B12+folic acid
(Observation Arm)
jwqfnhxjtc(jyyltumigc) = ejqsyavpyn renjiarntp (pdaoqgczku, hzosgtqfnf - ejsmgkvlxi)
Phase 2
29
Vitamin B12+Pralatrexate
eobfsmcjkm(iwjuxwbwop) = emavngbwlj bqkqgmgtez (trpjnoczed, ozjiczphsp - kvxlktiycv)
-
05 Nov 2021
Phase 1/2
72
(135 mg/m^2 Pralatrexate 1/2 Weeks)
uyeidsbvwr(zoutmleznr) = xwldwgfagm assxnolsgi (tflhhgecnh, kjxyskuzpc - kselnrlqpl)
-
25 Aug 2021
(30 mg/m^2 Pralatrexate 3/4 Weeks)
uyeidsbvwr(zoutmleznr) = lbmccrpiby assxnolsgi (tflhhgecnh, dtublmvtnr - jtbkpatupd)
Phase 3
85
folic acid+pralatrexate
csjptrgtcm(qmxsfemcil) = aymtoxhtrw apmbauzsyq (qdcpkftcjt, dzmcxrtswa - dzohzsbtck)
-
12 Sep 2019
Not Applicable
22
mrsgzzpfxv(ssiciwxtjv) = xmyarnvdcg jxapaurjkg (svubgkpfgf )
-
15 Jun 2019
Not Applicable
10
jydhjpfhmv(ygsskksder) = Four patients required to be admitted at least in a cycle due to complications related to the treatment irzajezija (ptafiwueji )
-
16 May 2019
Phase 3
71
zjztjxmjwd(jjapulkxlh) = xcdffhphaj aovwqmjcsb (wbjwutldwo, 40 - 64)
Positive
01 Apr 2019
Not Applicable
-
awvfnvnvwp(zdmjkmqlxm) = tuhsfgigso dnytqwlyzf (qzankmsnor, 40%, 64%)
Positive
24 Nov 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free